MedTrace Logo

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NCT02257619 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-04-21

No results posted yet for this study

Summary

The primary objectives of this study were to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion), and to evaluate and compare the overall survival of subjects with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) when treated with itacitinib in combination with docetaxel versus docetaxel alone (Part 2, randomized portion).

Conditions

  • NSCLC (Non-small Cell Lung Carcinoma)

Interventions

DRUG

Itacitinib

Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.

DRUG

docetaxel

Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.

Sponsors & Collaborators

Principal Investigators

  • Amit Pande, M.D. · Incyte Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-24
Primary Completion
2016-02-29
Completion
2016-04-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02257619 on ClinicalTrials.gov